Biocept Bilan de santé
Santé financière contrôle des critères 2/6
Biocept has a total shareholder equity of $290.0K and total debt of $526.0K, which brings its debt-to-equity ratio to 181.4%. Its total assets and total liabilities are $22.1M and $21.8M respectively.
Informations clés
181.4%
Ratio d'endettement
US$526.00k
Dette
Ratio de couverture des intérêts | n/a |
Argent liquide | US$6.63m |
Fonds propres | US$290.00k |
Total du passif | US$21.81m |
Total des actifs | US$22.10m |
Mises à jour récentes de la santé financière
Recent updates
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth
Apr 17Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position
Nov 23Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings
Aug 19Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being
Jul 03Biocept and CLEARED4 ink collaboration agreement
Jun 09Biocept enters COVID-19 testing partnership
Apr 28Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain
Mar 13We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate
Jan 26Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?
Dec 22Biocept's assays viable and sensitive for detecting tumor cells and biomarkers
Nov 20Biocept +4% on COVID-19 testing update
Nov 12Analyse de la situation financière
Passif à court terme: BIOC's short term assets ($8.9M) exceed its short term liabilities ($4.9M).
Passif à long terme: BIOC's short term assets ($8.9M) do not cover its long term liabilities ($16.9M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: BIOC has more cash than its total debt.
Réduire la dette: BIOC's debt to equity ratio has increased from 20% to 181.4% over the past 5 years.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: BIOC has less than a year of cash runway based on its current free cash flow.
Prévisions de trésorerie: BIOC has less than a year of cash runway if free cash flow continues to grow at historical rates of 15.3% each year.